Tscan Therapeutics Inc (TCRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.89M
Last updated: Nov 17, 2026 at 4:15 PM ET
Tscan Therapeutics Inc (TCRX) Statistics
Tscan Therapeutics (TCRX) has a market cap of $10.89M. It kept -2219.19% of revenue as net income over the last 12 months. It holds $40.07M more cash than debt, 368.07% of its market cap.
Total Valuation
| Market Cap | $10.89M |
|---|---|
| Latest price (Nov 17, 2026) | $0.15 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.8x and 0.5x. Its year-end P/S ranged from 1.9x to 121.4x from 2021 to 2025.
| P/S Ratio | 3.8x |
|---|---|
| Forward P/S | 3.4x |
| P/B Ratio | 0.5x |
Price Statistics
The stock is down 86.27% over 52 weeks and trades 40.00% below its 50-day average.
| Beta (1Y) | 1.83 |
|---|---|
| 52-Week Change | -86.27% |
| 1-Month Change | -28.16% |
| 3-Month Change | -79.87% |
| 6-Month Change | -84.32% |
| 5-Year Change | -98.01% |
| Total Return (1Y) | -86.27% |
| Total Return (3Y CAGR) | -69.54% |
| Total Return (5Y CAGR) | -55.62% |
| Max Drawdown (1Y) | -89.85% |
| Max Drawdown (3Y) | -98.47% |
| Sharpe Ratio (1Y) | -1.89 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $0.25 |
| 200-Day Average | $0.80 |
| 52-Week Range | $0.14 to $1.47 |
| RSI (14 Days) | 30.7 |
| Average Volume (20 Days) | 450.42K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.03x current liabilities, and total debt is 0.87x shareholder equity.
| Current Ratio | 2.03x |
|---|---|
| Quick Ratio | 2.03x |
| Debt / Equity | 0.87x |
| Interest Coverage | -40.69x |
Returns and Efficiency
Return on invested capital is -129.74% over the last 12 months, against a 5-year average of -47.41%.
| Return on Equity (ROE) | -302.77% |
|---|---|
| Return on Assets (ROA) | -81.39% |
| Return on Invested Capital (ROIC) | -129.74% |
| ROE (5Y Average) | -62.86% |
| ROA (5Y Average) | -36.59% |
| ROIC (5Y Average) | -47.41% |
| Asset Turnover | 0.03x |
Scores
TCRX has an Altman Z-Score of -8.15, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -8.15 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $5.19M over the last 12 months is down 38.43% from the 12 months before.
| Revenue | $5.19M |
|---|---|
| Revenue Growth (YoY) | -38.43% |
| Gross Profit | $5.19M |
| Operating Income | -$116.52M |
| Pretax Income | -$115.14M |
| Net Income | -$115.09M |
| EBITDA | -$113.78M |
| Reported EPS (TTM) | -$0.88 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 26.88% of the $141.40M in total assets.
| Cash and Equivalents | $73.04M |
|---|---|
| Total Debt | $32.97M |
| Net Cash | $40.07M |
| Net Cash Per Share | $0.31 |
| Working Capital | $38.97M |
| Shareholder Equity | $38.01M |
| Book Value Per Share | $0.29 |
| Total Assets | $141.40M |
| Total Liabilities | $103.39M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $775.00K of capital spending, operating cash flow left -$111.67M of free cash flow.
| Operating Cash Flow | -$110.89M |
|---|---|
| Capital Expenditures | $775.00K |
| Free Cash Flow | -$111.67M |
| FCF Per Share | -$1.76 |
| Depreciation and Amortization | $2.79M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2246.84%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2246.84% |
| Pretax Margin | -2220.23% |
| Net Margin | -2219.19% |
| EBITDA Margin | -2194.02% |
| FCF Margin | -2153.26% |
Growth
Revenue fell 8.63% a year over 3 years.
| Revenue Growth (3Y CAGR) | -8.63% |
|---|---|
| Revenue Growth (5Y CAGR) | +56.92% |
| Book Value Per Share Growth (2Y CAGR) | -22.80% |
| Tangible Book Per Share Growth (2Y CAGR) | -22.80% |
Dividends and Yields
TCRX does not pay a dividend. Its free cash flow yield is -568.75%.
| FCF Yield | -568.75% |
|---|---|
| Buyback Yield | -0.88% |
| Shareholder Yield | -0.88% |
Peer Position
Against 4 similar companies, TCRX has the 4th highest P/S.
P/S RatioPeer median 15.6x
ROICPeer median -281.41%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -41.95%
| P/S Ratio | 3.8x vs 15.6x median |
|---|---|
| ROIC | -129.74% vs -281.41% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -38.43% vs -41.95% median |
Analyst Forecast
Consensus estimates put revenue growth at -59.82% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -59.82% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TCRX
What is TCRX's market cap?
Tscan Therapeutics has a market cap of $10.89M.
How many shares of TCRX are outstanding?
Tscan Therapeutics has 130.03M shares outstanding. The count is up 0.15% from a year earlier.
Does TCRX pay a dividend?
No. Tscan Therapeutics does not pay a dividend.
How much debt does TCRX have?
Tscan Therapeutics has $32.97M of total debt and $73.04M of cash and equivalents, a net cash position of $40.07M.
TCRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors